Dynavax Technologies Corporation (DVAX): Price and Financial Metrics
DVAX Price/Volume Stats
| Current price | $11.38 | 52-week high | $15.15 |
| Prev. close | $11.76 | 52-week low | $10.06 |
| Day low | $11.36 | Volume | 406,489 |
| Day high | $11.75 | Avg. volume | 2,022,830 |
| 50-day MA | $12.27 | Dividend yield | N/A |
| 200-day MA | $13.53 | Market Cap | 1.49B |
DVAX Stock Price Chart Interactive Chart >
Dynavax Technologies Corporation (DVAX) Company Bio
Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company, using TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. The company was founded in 1996 and is based in Berkeley, California.
Latest DVAX News From Around the Web
Below are the latest news stories about DYNAVAX TECHNOLOGIES CORP that investors may wish to consider to help them evaluate DVAX as an investment opportunity.
Mirum (MIRM) Down on Failure of Mid-Stage Study on LivmarliMirum (MIRM) faces a setback in its efforts to expand its lead drug Livmarli's label for the indication of biliary atresia in patients who have undergone a Kasai surgery. |
NextCure (NXTC) Down on Shelving Plans to Develop CandidateNextCure (NXTC) plans to focus on developing LNCB74 and stop the development of NC762 to conserve cash. The company's shares decline on the same. |
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?Here is how Aquestive Therapeutics (AQST) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year. |
Can Dynavax Technologies (DVAX) Climb 91.59% to Reach the Level Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 91.6% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's HowKiniksa Pharmaceuticals (KNSA) enjoys a good run in the year on the back of solid revenue growth and pipeline updates. |
DVAX Price Returns
| 1-mo | -8.96% |
| 3-mo | -17.24% |
| 6-mo | -20.03% |
| 1-year | 6.06% |
| 3-year | 18.67% |
| 5-year | 67.35% |
| YTD | -18.60% |
| 2023 | 31.39% |
| 2022 | -24.38% |
| 2021 | 216.18% |
| 2020 | -22.20% |
| 2019 | -37.49% |
Continue Researching DVAX
Want to see what other sources are saying about Dynavax Technologies Corp's financials and stock price? Try the links below:Dynavax Technologies Corp (DVAX) Stock Price | Nasdaq
Dynavax Technologies Corp (DVAX) Stock Quote, History and News - Yahoo Finance
Dynavax Technologies Corp (DVAX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...